Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511913 · ClinicalTrials.gov registry record
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,411
- Enrollment target
NCT01511913 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,411 participants.
The verdict
NCT01511913 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,411 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,411 participants |
| Start Date | 2012-06-03 |
| Est. Completion | 2019-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511913
The ClinicalTrials.gov registry entry for NCT01511913 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01511913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511913 about?
NCT01511913 is a clinical study titled "A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma". The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
What is the current status of trial NCT01511913?
This trial is currently completed. The enrollment target is 1,411 participants. The study started on 2012-06-03. Estimated completion is 2019-12-12.
Who is sponsoring clinical trial NCT01511913?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.